Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Rosuvastatin DDI Study
NCT02186483Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin and rosuvastatin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (3 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Steady State at 32 hours and Area Under the Curve over the Dosing Interval at 32 hours. Started Aug 2014; status: completed.
02
Drugs
metforminrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT02186483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186483.